Pre- and Post-Portosystemic Shunt Placement Metabolomics Reveal Molecular Signatures for the Development of Hepatic Encephalopathy

Hepatic encephalopathy (HE) is a common complication of advanced liver disease causing brain dysfunction. This is likely due to the accumulation of unfiltered toxins within the bloodstream. A known risk factor for developing or worsening HE is the placement of a transjugular intrahepatic portosystemic shunt (TIPS), which connects the pre-hepatic and post-hepatic circulation allowing some blood to bypass the dysfunctional liver and decreases portal hypertension. To better understand the pathophysiology of post-TIPS HE, we conducted a multi-center prospective cohort study employing metabolomic analyses on hepatic vein and peripheral vein blood samples from participants with cirrhosis undergoing elective TIPS placement, measuring chemical modifications and changes in concentrations of metabolites resulting from TIPS placement. In doing so, we identified numerous alterations in metabolites, including bile acids, glycerophosphocholines, and bilirubins possibly implicated in the development and severity of HE.

[1]  A. Albanese,et al.  Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases , 2022, Translational Neurodegeneration.

[2]  Emma L. Schymanski,et al.  Open Access Repository-Scale Propagated Nearest Neighbor Suspect Spectral Library for Untargeted Metabolomics , 2022, bioRxiv.

[3]  S. DeMorrow,et al.  A critical review of bile acids and their receptors in hepatic encephalopathy. , 2021, Analytical biochemistry.

[4]  P. Dorrestein,et al.  Mass spectrometry-based metabolomics in microbiome investigations , 2021, Nature Reviews Microbiology.

[5]  Xinran Lin,et al.  Psoas Muscle Density Predicts Occurrences of Hepatic Encephalopathy in Patients Receiving Transjugular Intrahepatic Portosystemic Shunts within 1 year , 2021, CardioVascular and Interventional Radiology.

[6]  Jinbao Liu,et al.  Pathological Significance and Prognostic Roles of Indirect Bilirubin/Albumin Ratio in Hepatic Encephalopathy , 2021, Frontiers in Medicine.

[7]  Edward A. Lee,et al.  North American Practice-Based Recommendations for Transjugular Intrahepatic Portosystemic Shunts in Portal Hypertension. , 2021, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  Emily C. Gentry,et al.  Ion identity molecular networking for mass spectrometry-based metabolomics in the GNPS environment , 2021, Nature Communications.

[9]  R. Butterworth Ammonia Removal by Metabolic Scavengers for the Prevention and Treatment of Hepatic Encephalopathy in Cirrhosis , 2021, Drugs in R&D.

[10]  Mingxun Wang,et al.  Chemical Proportionality within Molecular Networks. , 2021, Analytical chemistry.

[11]  A. Petersen,et al.  Fecal microbiota transplantation in hepatic encephalopathy: a systematic review , 2021, Scandinavian journal of gastroenterology.

[12]  E. Carneiro,et al.  The bile acid TUDCA and neurodegenerative disorders: An overview. , 2021, Life sciences.

[13]  H. Khara,et al.  A Comprehensive Review Evaluating the Impact of Protein Source (Vegetarian vs. Meat Based) in Hepatic Encephalopathy , 2021, Nutrients.

[14]  Allegra T. Aron,et al.  Siderophore-mediated zinc acquisition enhances enterobacterial colonization of the inflamed gut , 2020, bioRxiv.

[15]  Justin J. J. van der Hooft,et al.  ReDU: a framework to find and reanalyze public mass spectrometry data , 2020, Nature Methods.

[16]  J. Takanashi,et al.  Neurochemistry of hyponatremic encephalopathy evaluated by MR spectroscopy , 2020, Brain and Development.

[17]  F. Gao,et al.  Efficacy of albumin-bilirubin score to predict hepatic encephalopathy in patients underwent transjugular intrahepatic portosystemic shunt. , 2020, European journal of gastroenterology & hepatology.

[18]  A. Saraya,et al.  Persistent or incident hyperammonemia is associated with poor outcomes in acute decompensation and acute‐on‐chronic liver failure , 2020, JGH open : an open access journal of gastroenterology and hepatology.

[19]  Julie C. Lumeng,et al.  Global chemical effects of the microbiome include new bile-acid conjugations , 2020, Nature.

[20]  Simon Rogers,et al.  Feature-Based Molecular Networking in the GNPS Analysis Environment , 2019, Nature Methods.

[21]  Rob Knight,et al.  Metabolome-Informed Microbiome Analysis Refines Metadata Classifications and Reveals Unexpected Medication Transfer in Captive Cheetahs , 2019, mSystems.

[22]  D. Rockey,et al.  Ammonia Levels Do Not Guide Clinical Management of Patients With Hepatic Encephalopathy Caused by Cirrhosis. , 2020, The American journal of gastroenterology.

[23]  Eric E. Allen,et al.  Visualizing ’omic feature rankings and log-ratios using Qurro , 2019, bioRxiv.

[24]  F. Behar-Cohen,et al.  Review: The bile acids urso- and tauroursodeoxycholic acid as neuroprotective therapies in retinal disease , 2019, Molecular vision.

[25]  Wei Jia,et al.  Emerging Applications of Metabolomics in Clinical Pharmacology , 2019, Clinical pharmacology and therapeutics.

[26]  Francesco Asnicar,et al.  Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2 , 2019, Nature Biotechnology.

[27]  Karsten Zengler,et al.  A Novel Sparse Compositional Technique Reveals Microbial Perturbations , 2019, mSystems.

[28]  K. Weissenborn Hepatic Encephalopathy: Definition, Clinical Grading and Diagnostic Principles , 2019, Drugs.

[29]  William H. Bisson,et al.  Gut microbiota and intestinal FXR mediate the clinical benefits of metformin , 2018, Nature Medicine.

[30]  M. Lungren,et al.  Albumin-Bilirubin Score: An Accurate Predictor of Hepatic Decompensation in High-Risk Patients Undergoing Transarterial Chemoembolization for Hepatocellular Carcinoma. , 2018, Journal of vascular and interventional radiology : JVIR.

[31]  G. Werstuck,et al.  Untargeted Metabolomics in the Discovery of Novel Biomarkers and Therapeutic Targets for Atherosclerotic Cardiovascular Diseases. , 2018, Cardiovascular & hematological disorders drug targets.

[32]  Justine W. Debelius,et al.  The gut–liver axis and the intersection with the microbiome , 2018, Nature Reviews Gastroenterology & Hepatology.

[33]  C. Trautwein,et al.  Role of bile acids in the gut-liver axis. , 2018, Journal of hepatology.

[34]  A. Petrescu,et al.  FXR-Mediated Cortical Cholesterol Accumulation Contributes to the Pathogenesis of Type A Hepatic Encephalopathy , 2018, Cellular and molecular gastroenterology and hepatology.

[35]  U. Sauer,et al.  High-throughput metabolomic analysis predicts mode of action of uncharacterized antimicrobial compounds , 2018, Science Translational Medicine.

[36]  Pieter C. Dorrestein,et al.  Meta-mass shift chemical profiling of metabolomes from coral reefs , 2017, Proceedings of the National Academy of Sciences.

[37]  O. Fiehn,et al.  Metabolite Measurement: Pitfalls to Avoid and Practices to Follow. , 2017, Annual Review of Biochemistry.

[38]  P. Bosma,et al.  Biliverdin Reductase inhibitors did not improve severe unconjugated hyperbilirubinemia in vivo , 2017, Scientific Reports.

[39]  Pieter C Dorrestein,et al.  Molecular Networking As a Drug Discovery, Drug Metabolism, and Precision Medicine Strategy. , 2017, Trends in pharmacological sciences.

[40]  N. Méndez-Sánchez,et al.  The Role of the Gut Microbiota in Bile Acid Metabolism. , 2017, Annals of hepatology.

[41]  N. Weiss,et al.  Cerebrospinal fluid metabolomics highlights dysregulation of energy metabolism in overt hepatic encephalopathy. , 2016, Journal of hepatology.

[42]  Kristian Fog Nielsen,et al.  Sharing and community curation of mass spectrometry data with Global Natural Products Social Molecular Networking , 2016, Nature Biotechnology.

[43]  D. Wishart Emerging applications of metabolomics in drug discovery and precision medicine , 2016, Nature Reviews Drug Discovery.

[44]  M. Morgan,et al.  Non-absorbable disaccharides versus placebo/no intervention and lactulose versus lactitol for the prevention and treatment of hepatic encephalopathy in people with cirrhosis. , 2016, The Cochrane database of systematic reviews.

[45]  Rui F. M. Silva,et al.  Hydrophilic bile acids protect human blood-brain barrier endothelial cells from disruption by unconjugated bilirubin: an in vitro study , 2015, Front. Neurosci..

[46]  A. Krag,et al.  Systematic review with meta‐analysis: the effects of rifaximin in hepatic encephalopathy , 2014, Alimentary pharmacology & therapeutics.

[47]  D. Bates,et al.  Fitting Linear Mixed-Effects Models Using lme4 , 2014, 1406.5823.

[48]  R. Knight,et al.  Finding the missing links among metabolites, microbes, and the host. , 2014, Immunity.

[49]  Matthew McMillin,et al.  Bile acids permeabilize the blood brain barrier after bile duct ligation in rats via Rac1-dependent mechanisms. , 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[50]  P. Hylemon,et al.  Bile acids and the gut microbiome , 2014, Current opinion in gastroenterology.

[51]  L. Ursell,et al.  The intestinal metabolome: an intersection between microbiota and host. , 2014, Gastroenterology.

[52]  B. Runyon,et al.  Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012 , 2013, Hepatology.

[53]  M. Kukla Angiogenesis: a phenomenon which aggravates chronic liver disease progression , 2013, Hepatology International.

[54]  Rui F. M. Silva,et al.  Neuritic growth impairment and cell death by unconjugated bilirubin is mediated by NO and glutamate, modulated by microglia, and prevented by glycoursodeoxycholic acid and interleukin-10 , 2012, Neuropharmacology.

[55]  G. Auzinger,et al.  Infection and systemic inflammation, not ammonia, are associated with Grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. , 2011, Journal of hepatology.

[56]  S. Coulon,et al.  Angiogenesis in chronic liver disease and its complications , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[57]  Mercedes Fernandez,et al.  Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. , 2010, Journal of hepatology.

[58]  B. S. Mohammed,et al.  Tauroursodeoxycholic Acid May Improve Liver and Muscle but Not Adipose Tissue Insulin Sensitivity in Obese Men and Women , 2010, Diabetes.

[59]  H. Bernstein,et al.  Protective effects of glycoursodeoxycholic acid in Barrett's esophagus cells. , 2010, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[60]  Á. Almeida,et al.  Bilirubin selectively inhibits cytochrome c oxidase activity and induces apoptosis in immature cortical neurons: assessment of the protective effects of glycoursodeoxycholic acid , 2010, Journal of neurochemistry.

[61]  David S. Wishart,et al.  MetaboAnalyst: a web server for metabolomic data analysis and interpretation , 2009, Nucleic Acids Res..

[62]  J. Watchko,et al.  Calculated free bilirubin levels and neurotoxicity , 2009, Journal of Perinatology.

[63]  Zsuzsanna Lipták,et al.  SIRIUS: decomposing isotope patterns for metabolite identification , 2008, Bioinform..

[64]  W. Byrne,et al.  Hepatic encephalopathy. , 2009, Emergency medicine clinics of North America.

[65]  J. Bosch,et al.  Portal hypertension and its complications. , 2008, Gastroenterology.

[66]  Rui F. M. Silva,et al.  Bilirubin injury to neurons: contribution of oxidative stress and rescue by glycoursodeoxycholic acid. , 2008, Neurotoxicology.

[67]  Rui F. M. Silva,et al.  Glycoursodeoxycholic Acid and Interleukin-10 Modulate the Reactivity of Rat Cortical Astrocytes to Unconjugated Bilirubin , 2007, Journal of neuropathology and experimental neurology.

[68]  Nigel W. Hardy,et al.  Proposed minimum reporting standards for chemical analysis , 2007, Metabolomics.

[69]  D. Amarapurkar,et al.  Angiogenesis in chronic liver disease. , 2007, Annals of hepatology.

[70]  G. Kikuchi,et al.  Heme oxygenase and heme degradation. , 2003, Biochemical and biophysical research communications.

[71]  U. Wosiewitz,et al.  Solubilization of unconjugated bilirubin by bile salts , 1979, Experientia.

[72]  J. Palmaz Transjugular intrahepatic portosystemic shunt. , 2020, Clinical privilege white paper.

[73]  Alan H. Lockwood,et al.  Blood Ammonia Levels and Hepatic Encephalopathy , 2004, Metabolic Brain Disease.

[74]  F. Sánchez‐Madrid,et al.  Angiogenesis in chronic inflammatory liver disease , 2004, Hepatology.

[75]  À. Rovira,et al.  1H Magnetic Resonance in the Study of Hepatic Encephalopathy in Humans , 2002, Metabolic Brain Disease.

[76]  Frederick Van Lente,et al.  Correlation between ammonia levels and the severity of hepatic encephalopathy. , 2003, The American journal of medicine.

[77]  S. Bluml,et al.  Proton‐Decoupled 31P Magnetic Resonance Spectroscopy Reveals Osmotic and Metabolic Disturbances in Human Hepatic Encephalopathy , 1998, Journal of neurochemistry.

[78]  P. Bosma,et al.  Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. , 1994, The Journal of biological chemistry.

[79]  T. Aikawa,et al.  Physiologic Measurement of Intrahepatic Shunted Blood Flow By Means of D-Galactose-1-C 14 , 1971, Angiology.